^
    15h
    EVER-132-001: Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments (clinicaltrials.gov)
    P2, N=80, Active, not recruiting, Gilead Sciences | Trial completion date: Dec 2025 --> Dec 2027
    Trial completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    Trodelvy (sacituzumab govitecan-hziy)
    18h
    Combined positive score status in metastatic triple-negative breast cancer patients treated with sacituzumab govitecan: associated clinical characteristics and testing patterns in a Central European cohort. (PubMed, Clin Transl Oncol)
    In this selected cohort, CPS status did not correlate with clinicopathological characteristics, but CPS-positive status was associated with inferior survival outcomes. Given the selection and survivor bias inherent to later-line treatment cohorts and the incomplete availability of CPS, these findings should be considered hypothesis-generating.
    Clinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Trodelvy (sacituzumab govitecan-hziy)
    2d
    TROPICS-03: Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors (clinicaltrials.gov)
    P2, N=223, Active, not recruiting, Gilead Sciences | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Trodelvy (sacituzumab govitecan-hziy)
    3d
    A Phase II Exploratory Study of Sacituzumab Tirumotecan (Sac-TMT/SKB264) in Combination with Bevacizumab for Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An Open-Label, Multicenter Clinical Trial (ChiCTR2500108816)
    P2, N=38, Not yet recruiting, The First Affiliated Hospital of Wenzhou Medical UniversitynThe First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliate | Initiation date: Sep 2025 --> Feb 2026
    Trial initiation date
    |
    Avastin (bevacizumab) • Trodelvy (sacituzumab govitecan-hziy) • Jiataile (sacituzumab tirumotecan)
    3d
    A Clinical Study on the Use of Yuyang Mouthwash for the Prevention of Grade ≥2 Sacituzumab Govitecan–Associated Oral Mucositis (ChiCTR2500114861)
    P=N/A, N=303, Not yet recruiting, Beijing Luhe Medical College Affiliated to Capital Medical University; Beijing Luhe Medical College Affiliated to Capital Medical University
    New trial
    |
    Trodelvy (sacituzumab govitecan-hziy)
    3d
    Switching to Sacituzumab Govitecan Combined Toripalimab in TNBC Patients:Tumor Non-Response After the First Stage of NC A Single-Arm Clinical Study to Explore the Efficacy and Safety (ChiCTR2500112392)
    P=N/A, N=31, Not yet recruiting, Fujian Medical University Union Hospital; Fujian Medical University Union Hospital
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Loqtorzi (toripalimab-tpzi) • Trodelvy (sacituzumab govitecan-hziy) • Jiataile (sacituzumab tirumotecan)
    3d
    The Pilot Study on Sacituzumab tirumotecan (SKB264) for the Treatment of Recurrent Adamantinomatous Craniopharyngioma (ACP) (ChiCTR2500111542)
    P=N/A, N=12, Not yet recruiting, Xuanwu Hospital, Capital Medical University; Xuanwu Hospital, Capital Medical University
    New trial
    |
    Jiataile (sacituzumab tirumotecan)
    3d
    Clinical Study of ctDNA Dynamic Monitoring in Sacituzumab tirumotecan for EGFR-Mutated Non-Squamous NSCLC After EGFR-TKI Failure (ChiCTR2600115950)
    P4, N=30, Not yet recruiting, Shaanxi Provincial Cancer Hospital; Shaanxi Provincial Cancer Hospital
    New P4 trial
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    Jiataile (sacituzumab tirumotecan)
    3d
    Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer (ChiCTR2500112194)
    P4, N=30, Not yet recruiting, The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University
    New P4 trial
    |
    Avastin (bevacizumab) • Jiataile (sacituzumab tirumotecan)
    3d
    Sintilimab Combined with Sacituzumab tirumotecan in Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Single-Arm, Single-Center, Phase II Clinical Study (ChiCTR2500111980)
    P4, N=49, Not yet recruiting, Tangdu Hospital, Fourth Military Medical University; Tangdu Hospital, Fourth Military Medical University
    New P4 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tyvyt (sintilimab) • Jiataile (sacituzumab tirumotecan)
    3d
    A Single-arm, Single-center Phase II Clinical Study of Sacituzumab tirumotecan Combined with Anlotinib in the Second-line Treatment of Patients with Advanced Gastric Cancer (ChiCTR2500112073)
    P4, N=33, Not yet recruiting, The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University
    New P4 trial
    |
    Focus V (anlotinib) • Jiataile (sacituzumab tirumotecan)
    3d
    A prospective single-arm phase II clinical trial on the sacituzumab tirumotecan treatment of targeted therapy pre-treated, advanced or metastatic non-small cell lung cancer patients with EGFR uncommon mutations (ChiCTR2500114453)
    P2, N=30, Not yet recruiting, Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Jiataile (sacituzumab tirumotecan)